10 Xue M, Chen K J, Yin H J. Relationship between platelet activation related factors and polymorphism of ralated genes in patients with coronary heart disease of blood-stasis syndrome. Chin J Integr Med, 2008, 14: 267-273
27 Yao Y, Wu W Y, Liu A H, et al. Interaetion of salvianolic acids and notoginsengnosides in inhibition of ADP-induced platelet aggregation. Am J Chin Med, 2008, 36: 313-328
34 Furman M I, Benoit S E, Barnard M R, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol, 1998, 31: 352-358
[19]
35 Liu Y, Yin H J, Jiang Y R, et al. Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease. Chin J Integr Med, 2011, 17: 587-592
44 Yacoub D, Théorêt J F, Villeneuve L, et al. Essential role of protein kinase Cδ in platelet signaling, aⅡbβ3 activation, and thromboxane A2 release. J Biol Chem, 2006, 281: 30024-30035
[25]
45 Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science, 1992, 258: 607-614
[26]
46 Yang Y M, Wang X X, Chen J Z, et al. Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med, 2008, 36: 603-613
[27]
47 Kaplan K L, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood, 1981, 57: 199-202
[28]
48 Pumphrey C W, Dawes J. Plasma beta-thromboglobulin as a measure of platelet activity: Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction. Am J Cardiol, 1982, 50: 1258-1261
69 Cosemans J M, Munnix I C, Wetzker R, et al. Continuous signaling via PI3K isoforms β and γ is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood, 2006, 108: 3045-3052
[40]
70 Li Z, Zhang G, Le Breton G C, et al. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem, 2003, 278: 30725-30731
[41]
72 Huang Z S, Zeng C L, Zhu L J, et al. Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase. J Thromb Haemost, 2010, 8: 1383-1393
[42]
74 García A. Clinical proteomics in platelet research: Challenges ahead. J Thromb Haemost, 2010, 8: 1784-1785
[43]
75 Senzel L, Gnatenko D V, Bahou W F. The platelet proteome. Curr Opin Hematol, 2009, 16: 329-333
[44]
76 Banfi C, Brioschi M, Marenzi G, et al. Proteome of platelets in patients with coronary artery disease. Exp Hematol, 2010, 38: 341-350
82 Wang S L, Wang C L, Wang P L, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C trial): An open-label randomized controlled, multicenter study. Evid Based Complement Alternat Med, 2013, 2013: 741518
4 Gergely F, Andrea F, Gabriella P, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol, 2010, 2: 171-186
[50]
7 Juurlink D N, Gomes T, Ko D T, et al. A population-based study of the drug interaction between protonpump inhibitors and clopidogrel. Can Med Assoc J, 2009, 180: 713-718
3 Antithrombotic trialists' collaboration. Collaborate meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Brit Med J, 2002, 324: 71-86
[56]
5 Pena A, Collet J P, Hulot J S. Can we override clopidogrel resistance? Circulation, 2009, 119: 2854-2857
30 Hsu-Lin S, Berman C L, Furie B C, et al. A platelet membrane protein expressed during platelet activation and secretion: Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem, 1984, 259: 9121-9126
[62]
31 Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol, 1999, 6: 342-348
[63]
32 Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation, 1995, 92: 1693-1696
[64]
33 Shimomura H, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol, 1998, 81: 397-400
41 Kasirer-Friede A, Cozzi M R, Mazzucato M, et al. Signaling through GP-IX-V activates αⅡbβ3 independently of other receptors. Blood, 2004, 103: 3247-3606
49 Slungaard A. Platelet factor 4: A chemokine enigma. Int J Biochem Cell Biol, 2005, 37: 1162-1167
[70]
50 Hope W, Martin T J, Chesterman C N, et al. Human β-thromboglobulin inhibits PGI2 production and binds to specific site in bovine aortic endothelial cells. Nature, 1979, 282: 210-212
52 Kato M, Kambe M, Kajiyama G. Increased cytosolic free Mg2+ and Ca2+ in platelets of patients with vasospastic. Am J Physiol, 1998, 274: 548-554
[73]
53 Fujinishi A, Takahara K, Ohba C, et al. Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease. Angiology, 1997, 48: 515-521
[74]
56 Liu Y, Yin H J, Jiang Y R, et al. Correlation between platelet gelsolin and platelet activation level in acute myocardial infarction rats and intervention effect of effective components of Chuanxiong rhizome and red peony root. Evid Based Complement Alternat Med, 2013, 2013: 985746
77 Burkhart J M, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 2012, 120: e73-e82
81 Chen K J, Shi D Z, Xu H, et al. XS0601 reduces the incidence of restenosis: A prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J, 2006, 119: 6-13
